Small cell carcinoma of the prostate after low-dose-rate brachytherapy: a case report.
Chemotherapy
Immunotherapy
Ionizing radiotherapy
Low-dose-rate brachytherapy
Prostate cancer
Small cell carcinoma
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
28 Oct 2020
28 Oct 2020
Historique:
received:
14
06
2020
accepted:
08
09
2020
entrez:
28
10
2020
pubmed:
29
10
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Small cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease. Patients with metastatic disease are usually treated with platinum-based cytotoxic chemotherapy regimens similar to those used for small cell carcinoma of the lung. However, prognosis remains poor, with a median overall survival of 9 to 17 months despite therapy. This report describes a case of an 80-year-old Caucasian patient with lymph node and bone metastatic small cell carcinoma of the prostate following low-dose-rate brachytherapy for a low-risk prostate carcinoma and treated with chemotherapy and immunotherapy. Low-dose-rate brachytherapy might be an etiology of small cell prostate cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Small cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease. Patients with metastatic disease are usually treated with platinum-based cytotoxic chemotherapy regimens similar to those used for small cell carcinoma of the lung. However, prognosis remains poor, with a median overall survival of 9 to 17 months despite therapy.
CASE PRESENTATION
METHODS
This report describes a case of an 80-year-old Caucasian patient with lymph node and bone metastatic small cell carcinoma of the prostate following low-dose-rate brachytherapy for a low-risk prostate carcinoma and treated with chemotherapy and immunotherapy.
CONCLUSION
CONCLUSIONS
Low-dose-rate brachytherapy might be an etiology of small cell prostate cancer.
Identifiants
pubmed: 33109264
doi: 10.1186/s13256-020-02523-5
pii: 10.1186/s13256-020-02523-5
pmc: PMC7592557
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
203Références
Mod Pathol. 2011 Aug;24(8):1120-7
pubmed: 21499238
Am J Cancer Res. 2011;1(7):834-44
pubmed: 22016831
Urol Case Rep. 2017 Apr 26;13:61-62
pubmed: 28462157
Oncol Lett. 2013 Jan;5(1):53-56
pubmed: 23255893
Am J Cancer Res. 2014 Nov 19;4(6):850-61
pubmed: 25520873
Nat Rev Urol. 2014 Apr;11(4):213-9
pubmed: 24535589
J Clin Oncol. 2014 Oct 20;32(30):3383-90
pubmed: 25225419
Indian J Urol. 2009 Apr;25(2):259-63
pubmed: 19672363
Tumori. 2017 Nov 15;103(Suppl. 1):e56-e59
pubmed: 28623637
Prostate. 2009 May 1;69(6):603-9
pubmed: 19125417
J Natl Compr Canc Netw. 2014 May;12(5):719-26
pubmed: 24812138
Cancer Res. 2008 Dec 1;68(23):9663-70
pubmed: 19047143
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Med Imaging Radiat Oncol. 2010 Apr;54(2):100-7
pubmed: 20518871
Int J Clin Oncol. 2011 Dec;16(6):722-5
pubmed: 21347630